{
    "pmid": "41419094",
    "title": "Cardio-renal Outcomes in Type 2 Diabetes Patients with Advanced Chronic Kidney Disease on SGLT2 inhibitors or GLP-1 receptor agonists.",
    "abstract": "GLP-1 RA and SGLT2i have demonstrated cardio-renal protective effects in randomized clinical trials. However, their comparative cardio-renal benefits in diabetes patients with stage 4-5 chronic kidney disease remain underexplored. This is a retrospective study with target trial emulation design using TriNetX platform. Adults type 2 diabetes mellitus, stage 4-5 chronic kidney disease patients who were new initiation of GLP-1 RA compared to SGLT2i were enrolled. major adverse kidney events (MAKE), major adverse cardiovascular events (MACE), and all-cause mortality. Hazard ratios (HRs) were calculated for outcomes in 1:1 propensity score-matched patients. A total of 7,458 participants were included in each group, with a mean eGFR of 23-24 mL/min/1.73 mÂ². New users of GLP-1 RAs had a higher HR for MAKE (HR 1.05, 95% CI 1.0-1.1) & dialysis (HR 1.09, 95% CI 1.03-1.15), but similar HRs for all-cause mortality (HR 0.98, 95% CI 0.91-1.05) and MACE (HR 0.97, 95% CI 0.93-1.01) compared with SGLT2i users, despite a lower HR for heart failure (HR 0.94, 95% CI 0.90-0.99). Among new GLP-1 RA users, higher HRs for MAKE occurred in subgroup of males and patients without heart failure. In patients with type 2 diabetes and stage 4-5 chronic kidney disease, initiating an SGLT2i, relative to a GLP-1 RA, was associated with a lower risk of adverse kidney events and comparable cardiovascular and mortality risks. Further studies are warranted to confirm these findings.",
    "disease": "chronic kidney disease",
    "clean_text": "cardio renal outcomes in type diabetes patients with advanced chronic kidney disease on sglt inhibitors or glp receptor agonists glp ra and sglt i have demonstrated cardio renal protective effects in randomized clinical trials however their comparative cardio renal benefits in diabetes patients with stage chronic kidney disease remain underexplored this is a retrospective study with target trial emulation design using trinetx platform adults type diabetes mellitus stage chronic kidney disease patients who were new initiation of glp ra compared to sglt i were enrolled major adverse kidney events make major adverse cardiovascular events mace and all cause mortality hazard ratios hrs were calculated for outcomes in propensity score matched patients a total of participants were included in each group with a mean egfr of ml min m new users of glp ras had a higher hr for make hr ci dialysis hr ci but similar hrs for all cause mortality hr ci and mace hr ci compared with sglt i users despite a lower hr for heart failure hr ci among new glp ra users higher hrs for make occurred in subgroup of males and patients without heart failure in patients with type diabetes and stage chronic kidney disease initiating an sglt i relative to a glp ra was associated with a lower risk of adverse kidney events and comparable cardiovascular and mortality risks further studies are warranted to confirm these findings"
}